Kodiak Sciences Inc Common Stock KOD

$100.73 -9.41% at last close
Market Cap$6.59 billion
P/E Ratio—
Div Yield—
Volume980.4K
52-Week Range $10.94$112.79

Analyst Ratings

Consensus
Buy — 5 Buy · 1 Hold · 0 Sell (6 analysts)
Avg. Price Target
$97.33 (-3.4% downside)

Full KOD forecast & analyst actions →

Key Stats

Today's Range
$100.36 – $110.49
50-Day Range
$29.81 – $112.79
52-Week Range
$10.94 – $112.79
Volume
980K shs
Average Volume
1.07 million shs
Market Cap
$6.59 billion
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.01%
Days to Cover
1.00

About Kodiak Sciences Inc Common Stock

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
124
Exchange
XNAS
Listed
2018-10-04

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.